{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T14:47:43Z","timestamp":1794667663146,"version":"4.9.1"},"reference-count":78,"publisher":"BMJ","issue":"4","funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG 2019 number 23624"],"award-info":[{"award-number":["IG 2019 number 23624"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG 27531 to SG"],"award-info":[{"award-number":["IG 27531 to SG"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG 29289 to SC"],"award-info":[{"award-number":["IG 29289 to SC"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Italian Ministry of Health","doi-asserted-by":"crossref","award":["GR-2019-12371132"],"award-info":[{"award-number":["GR-2019-12371132"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003196","name":"Italian Ministry of Health","doi-asserted-by":"crossref","award":["Ricerca Corrente 2024-2025"],"award-info":[{"award-number":["Ricerca Corrente 2024-2025"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National University Health System Seed Fund","award":["NUHSRO\/2024\/008\/RO5+6\/Seed-Sep23\/01"],"award-info":[{"award-number":["NUHSRO\/2024\/008\/RO5+6\/Seed-Sep23\/01"]}],"id":[{"id":"https:\/\/ror.org\/05tjjsh18","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Singapore Ministry of Health\u2019s National Medical Research Council","award":["Open Fund-Large Collaborative Grant (\u201cOF-LCG\u201d)"],"award-info":[{"award-number":["Open Fund-Large Collaborative Grant (\u201cOF-LCG\u201d)"]}],"id":[{"id":"https:\/\/ror.org\/04x3cxs03","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Singapore Gastric Cancer Consortium","award":["Not Applicable"],"award-info":[{"award-number":["Not Applicable"]}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"crossref","award":["MOH-000967"],"award-info":[{"award-number":["MOH-000967"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"crossref","award":["NMRC\/ MOH-000627"],"award-info":[{"award-number":["NMRC\/ MOH-000627"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"crossref","award":["NMRC\/CIRG23Jul-0035"],"award-info":[{"award-number":["NMRC\/CIRG23Jul-0035"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the National University Hospital Singapore","award":["Chan Heng Leong Education & Research Fund 2024"],"award-info":[{"award-number":["Chan Heng Leong Education & Research Fund 2024"]}],"id":[{"id":"https:\/\/ror.org\/04fp9fm22","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000982","name":"Conquer Cancer, the ASCO Foundation","doi-asserted-by":"crossref","award":["2025 Conquer Cancer Merit Award"],"award-info":[{"award-number":["2025 Conquer Cancer Merit Award"]}],"id":[{"id":"10.13039\/100000982","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001381","name":"National Research Foundation, Singapore","doi-asserted-by":"crossref","award":["Not Applicable"],"award-info":[{"award-number":["Not Applicable"]}],"id":[{"id":"10.13039\/501100001381","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National University Hospital Junior Research Award 2023","award":["JRA\/Sep23\/002"],"award-info":[{"award-number":["JRA\/Sep23\/002"]}]},{"name":"Yong Loo Lin School of Medicine, National University of Singapore","award":["Dean\u2019s Research Development Award"],"award-info":[{"award-number":["Dean\u2019s Research Development Award"]}],"id":[{"id":"https:\/\/ror.org\/01tgyzw49","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Gut"],"accepted":{"date-parts":[[2025,10,9]]},"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Human epidermal growth factor receptor 2 (HER2;\n                      <jats:italic>ERBB2<\/jats:italic>\n                      ) is overexpressed or amplified in 15\u201320% of gastric cancers (HER2+ GC). Within individual HER2+ GCs, HER2\/\n                      <jats:italic>ERBB2<\/jats:italic>\n                      expression is often variable. Although HER2 therapeutic targeting improves outcomes for HER2+ GC patients, acquired resistance is frequent.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To spatially interrogate HER2+ GC interpatient and intrapatient heterogeneity and resistance mechanisms associated with HER2-targeting agents (trastuzumab, trastuzumab deruxtecan (T-DXd)).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Spatial transcriptomic analysis (GeoMx Digital Spatial Profiler) was applied to &gt;1500 regions of interest in 30 GCs\u2014these contained 15 HER2+ GCs treated with trastuzumab and T-DXd subsequently. Analysis of patient-matched samples with acquired trastuzumab or T-DXd resistance revealed escape mechanisms. Results were validated by immunohistochemistry, independent cohorts and patient-derived xenografts and organoids.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      HER2+ tumours exhibited\n                      <jats:italic>PD-L1<\/jats:italic>\n                      expression within the spatial tumour microenvironment. We observed increased expression of CLDN18.2, a promising therapeutic target, in trastuzumab-resistant tumours. One-third of HER2+ GC patients developed epithelial-mesenchymal transition (EMT) on trastuzumab resistance, associated with\n                      <jats:italic>PD-L1<\/jats:italic>\n                      and\n                      <jats:italic>CCL2<\/jats:italic>\n                      upregulation. Another third of trastuzumab-resistant HER2+ GC patients activated the endoplasmic reticulum-associated degradation (ERAD) pathway including genes such as\n                      <jats:italic>GOLM1<\/jats:italic>\n                      . HLA loss and increases in oxidative phosphorylation pathways were observed in T-DXd-resistant GCs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Our results delineate multiple acquired resistance mechanisms to trastuzumab and T-DXd in HER2+ GC\u2009\n                      <jats:italic>in vivo<\/jats:italic>\n                      . This information may guide trials combining trastuzumab or T-DXd with new agents to enhance the efficacy and durability of HER2 blockade.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/gutjnl-2024-334667","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:20:18Z","timestamp":1761844818000},"page":"733-747","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":30,"title":["Spatial profiling of patient-matched HER2 positive gastric cancer reveals resistance mechanisms to targeted therapy"],"prefix":"10.1136","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-6730-7963","authenticated-orcid":false,"given":"Taotao","family":"Sheng","sequence":"first","affiliation":[{"name":"Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9423-1368","authenticated-orcid":false,"given":"Raghav","family":"Sundar","sequence":"additional","affiliation":[{"name":"Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore"},{"name":"Yong Loo Lin School of Medicine, National University of Singapore, Singapore"},{"name":"Department of Haematology-Oncology, National University Cancer Institute, Singapore"},{"name":"Singapore Gastric Cancer Consortium, Singapore"},{"name":"Department of Medicine (Medical Oncology), Yale University, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supriya","family":"Srivastava","sequence":"additional","affiliation":[{"name":"Department of Medicine, National University Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuewen","family":"Ong","sequence":"additional","affiliation":[{"name":"Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Ting","family":"Tay","sequence":"additional","affiliation":[{"name":"Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoran","family":"Ma","sequence":"additional","affiliation":[{"name":"Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Uchihara","sequence":"additional","affiliation":[{"name":"Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedict Shi Xiang","family":"Lian","sequence":"additional","affiliation":[{"name":"Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Hagihara","sequence":"additional","affiliation":[{"name":"Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei Suen","family":"Kong","sequence":"additional","affiliation":[{"name":"Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5278-5063","authenticated-orcid":false,"given":"Chang","family":"Xu","sequence":"additional","affiliation":[{"name":"Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamaine Wei Ting","family":"Ho","sequence":"additional","affiliation":[{"name":"Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4104-8951","authenticated-orcid":false,"given":"Kie Kyon","family":"Huang","sequence":"additional","affiliation":[{"name":"Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angie Lay Keng","family":"Tan","sequence":"additional","affiliation":[{"name":"Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle Shu Wen","family":"NG","sequence":"additional","affiliation":[{"name":"Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiamin","family":"Toh","sequence":"additional","affiliation":[{"name":"Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara Shi Ya","family":"Ng","sequence":"additional","affiliation":[{"name":"Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Nasca","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara Carlotta","family":"Pircher","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Randon","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1854-1086","authenticated-orcid":false,"given":"Silvia","family":"Giordano","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Torino, Candiolo, Italy"},{"name":"Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Corso","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Torino, Candiolo, Italy"},{"name":"Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey Huey Yew","family":"Lum","sequence":"additional","affiliation":[{"name":"Department of Pathology, National University Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Teh","sequence":"additional","affiliation":[{"name":"Department of Pathology, National University Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph J","family":"Zhao","sequence":"additional","affiliation":[{"name":"Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore"},{"name":"Yong Loo Lin School of Medicine, National University of Singapore, Singapore"},{"name":"Department of Haematology-Oncology, National University Cancer Institute, Singapore"},{"name":"Department of Medicine, National University Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmy Bok Yan","family":"So","sequence":"additional","affiliation":[{"name":"Yong Loo Lin School of Medicine, National University of Singapore, Singapore"},{"name":"Singapore Gastric Cancer Consortium, Singapore"},{"name":"Department of Surgery, National University of Singapore, Singapore"},{"name":"Department of Surgery, University Surgical Cluster, National University Health System, Singapore"},{"name":"NUS Centre for Cancer Research, National University of Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Sabella","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyam","family":"Prabhakar","sequence":"additional","affiliation":[{"name":"Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore"},{"name":"Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore"},{"name":"Cancer Science Institute of Singapore, National University of Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeeyun","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea"},{"name":"Department of Intelligent Precision Healthcare Convergence, Sungkyunkwan University, Suwon, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei Peng","family":"Yong","sequence":"additional","affiliation":[{"name":"Department of Haematology-Oncology, National University Cancer Institute, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew Chau Hsien","family":"Ng","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, National Cancer Centre, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Shitara","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, National Cancer Center Hospital East, Kashiwa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Gasparello","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Padua, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Fassan","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Padua, Padua, Italy"},{"name":"Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8530-8420","authenticated-orcid":false,"given":"Filippo","family":"Pietrantonio","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0179-8048","authenticated-orcid":false,"given":"Patrick","family":"Tan","sequence":"additional","affiliation":[{"name":"Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore"},{"name":"Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore"},{"name":"Singapore Gastric Cancer Consortium, Singapore"},{"name":"Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore"},{"name":"Singhealth\/Duke-NUS Institute of Precision Medicine, National Heart Centre, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"key":"2026030607501050000_75.4.733.1","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101404","article-title":"The current and future incidence and mortality of gastric cancer in 185 countries, 2020-40: A population-based modelling study","volume":"47","author":"Morgan","year":"2022","journal-title":"EClinicalMedicine"},{"key":"2026030607501050000_75.4.733.2","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.trecan.2023.11.001","article-title":"Targeting HER2 heterogeneity in breast and gastrointestinal cancers","volume":"10","author":"Valenza","year":"2024","journal-title":"Trends Cancer"},{"key":"2026030607501050000_75.4.733.3","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1093\/cei\/uxac007","article-title":"Immune microenvironment characteristics and their implications for immune checkpoint inhibitor efficacy in HER2-overexpressing gastric cancer","volume":"207","author":"Cen","year":"2022","journal-title":"Clin Exp Immunol"},{"key":"2026030607501050000_75.4.733.4","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.580045","article-title":"Expression of Human Epidermal Growth Factor Receptor-2 Status and Programmed Cell Death Protein-1 Ligand Is Associated With Prognosis in Gastric Cancer","volume":"10","author":"Lv","year":"2020","journal-title":"Front Oncol"},{"key":"2026030607501050000_75.4.733.5","first-page":"1775","article-title":"Tumor microenvironment immune types in gastric cancer are associated with mismatch repair however, not HER2 status","volume":"18","author":"Valentini","year":"2019","journal-title":"Oncol Lett"},{"key":"2026030607501050000_75.4.733.6","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-014-0430-7"},{"key":"2026030607501050000_75.4.733.7","doi-asserted-by":"crossref","first-page":"9262","DOI":"10.18632\/oncotarget.24265","article-title":"Prognostic implications of HER2 heterogeneity in gastric cancer","volume":"9","author":"Motoshima","year":"2018","journal-title":"Oncotarget"},{"key":"2026030607501050000_75.4.733.8","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-018-1464-0"},{"key":"2026030607501050000_75.4.733.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61121-X"},{"key":"2026030607501050000_75.4.733.10","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2014.912631"},{"key":"2026030607501050000_75.4.733.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004413"},{"key":"2026030607501050000_75.4.733.12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00215-2"},{"key":"2026030607501050000_75.4.733.13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2781"},{"key":"2026030607501050000_75.4.733.14","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-316522"},{"key":"2026030607501050000_75.4.733.15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-1785"},{"key":"2026030607501050000_75.4.733.16","doi-asserted-by":"publisher","DOI":"10.1172\/JCI75200"},{"key":"2026030607501050000_75.4.733.17","doi-asserted-by":"crossref","unstructured":"Zhou C , Feng X , Yuan F , et al . . CMAR 2018;Volume 10:3945\u201354. 10.2147\/CMAR.S172710","DOI":"10.2147\/CMAR.S172710"},{"key":"2026030607501050000_75.4.733.18","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-018-0204-5"},{"key":"2026030607501050000_75.4.733.19","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41417-017-0005-y","article-title":"miR-200c inhibits TGF-\u03b2-induced-EMT to restore trastuzumab sensitivity by targeting ZEB1 and ZEB2 in gastric cancer","volume":"25","author":"Zhou","year":"2018","journal-title":"Cancer Gene Ther"},{"key":"2026030607501050000_75.4.733.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2018.05.009"},{"key":"2026030607501050000_75.4.733.21","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-0716-0623-0_21"},{"key":"2026030607501050000_75.4.733.22","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-1166"},{"key":"2026030607501050000_75.4.733.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.07.027"},{"key":"2026030607501050000_75.4.733.24","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-022-01100-4"},{"key":"2026030607501050000_75.4.733.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.03.007"},{"key":"2026030607501050000_75.4.733.26","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.humpath.2016.10.025","article-title":"Gene amplification of CCNE1, CCND1, and CDK6 in gastric cancers detected by multiplex ligation-dependent probe amplification and fluorescence in situ hybridization","volume":"61","author":"Ooi","year":"2017","journal-title":"Hum Pathol"},{"key":"2026030607501050000_75.4.733.27","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0888"},{"key":"2026030607501050000_75.4.733.28","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2011.198"},{"key":"2026030607501050000_75.4.733.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2020.153229"},{"key":"2026030607501050000_75.4.733.30","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14051266","article-title":"HER2-CDH1 Interaction via Wnt\/B-Catenin Is Associated with Patients\u2019 Survival in HER2-Positive Metastatic Gastric Adenocarcinoma","volume":"14","author":"De Re","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026030607501050000_75.4.733.31","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1093\/annonc\/mdy034","article-title":"Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients","volume":"29","author":"Kim","year":"2018","journal-title":"Ann Oncol"},{"key":"2026030607501050000_75.4.733.32","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s10120-018-0891-1","article-title":"Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3)","volume":"22","author":"Seo","year":"2019","journal-title":"Gastric Cancer"},{"key":"2026030607501050000_75.4.733.33","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30408"},{"key":"2026030607501050000_75.4.733.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.09.024"},{"key":"2026030607501050000_75.4.733.35","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz199"},{"key":"2026030607501050000_75.4.733.36","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aay6017","article-title":"Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics","volume":"5","author":"Alshetaiwi","year":"2020","journal-title":"Sci Immunol"},{"key":"2026030607501050000_75.4.733.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2019.02.009"},{"key":"2026030607501050000_75.4.733.38","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-021-09065-z","article-title":"Immune landscape of advanced gastric cancer tumor microenvironment identifies immunotherapeutic relevant gene signature","volume":"21","author":"Zhang","year":"2021","journal-title":"BMC Cancer"},{"key":"2026030607501050000_75.4.733.39","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-1384"},{"key":"2026030607501050000_75.4.733.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.06.005"},{"key":"2026030607501050000_75.4.733.41","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-326483"},{"key":"2026030607501050000_75.4.733.42","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf2403"},{"key":"2026030607501050000_75.4.733.43","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abj8002","article-title":"Phenotypic heterogeneity driven by plasticity of the intermediate EMT state governs disease progression and metastasis in breast cancer","volume":"8","author":"Brown","year":"2022","journal-title":"Sci Adv"},{"key":"2026030607501050000_75.4.733.44","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41586-018-0040-3","article-title":"Identification of the tumour transition states occurring during EMT","volume":"556","author":"Pastushenko","year":"2018","journal-title":"Nature New Biol"},{"key":"2026030607501050000_75.4.733.45","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2013.442","article-title":"An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530)","volume":"4","author":"Huang","year":"2013","journal-title":"Cell Death Dis"},{"key":"2026030607501050000_75.4.733.46","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s10120-021-01165-w","article-title":"Personalized therapeutic strategies in HER2-driven gastric cancer","volume":"24","author":"Ughetto","year":"2021","journal-title":"Gastric Cancer"},{"key":"2026030607501050000_75.4.733.47","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/s41416-020-01138-3","article-title":"Trastuzumab upregulates programmed death ligand-1 expression through interaction with NK cells in gastric cancer","volume":"124","author":"Yamashita","year":"2021","journal-title":"Br J Cancer"},{"key":"2026030607501050000_75.4.733.48","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/nyas.13454","article-title":"Coagulation and fibrinolysis in gastric cancer","volume":"1404","author":"Repetto","year":"2017","journal-title":"Ann N Y Acad Sci"},{"key":"2026030607501050000_75.4.733.49","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005063","article-title":"CD40\u00d7HER2 bispecific antibody overcomes the CCL2-induced trastuzumab resistance in HER2-positive gastric cancer","volume":"10","author":"Sun","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026030607501050000_75.4.733.50","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-19-1172"},{"key":"2026030607501050000_75.4.733.51","doi-asserted-by":"publisher","DOI":"10.1038\/ncb0805-766"},{"key":"2026030607501050000_75.4.733.52","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aaa6922","article-title":"HER2-mTOR signaling\u2013driven breast cancer cells require ER-associated degradation to survive","volume":"8","author":"Singh","year":"2015","journal-title":"Sci Signal"},{"key":"2026030607501050000_75.4.733.53","doi-asserted-by":"publisher","DOI":"10.2147\/ott.S162447"},{"key":"2026030607501050000_75.4.733.54","first-page":"14","article-title":"Trop-2 protein as a therapeutic target: A focused review on Trop-2-based antibody-drug conjugates and their predictive biomarkers","volume":"22","author":"Vranic","year":"2022","journal-title":"Bosn J of Basic Med Sci"},{"key":"2026030607501050000_75.4.733.55","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06300-3"},{"key":"2026030607501050000_75.4.733.56","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0593"},{"key":"2026030607501050000_75.4.733.57","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201445289"},{"key":"2026030607501050000_75.4.733.58","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30481-9"},{"key":"2026030607501050000_75.4.733.59","unstructured":"Haoran Ma SS , Ong X , Tay ST , et al . Spatially Resolved Tumor Ecosystems and Cell States in Gastric Adenocarcinoma Progression and Evolution. bioRxiv 2024."},{"key":"2026030607501050000_75.4.733.60","doi-asserted-by":"crossref","DOI":"10.15252\/embr.201948058","article-title":"CDK12 drives breast tumor initiation and trastuzumab resistance via WNT and IRS1-ErbB-PI3K signaling","volume":"20","author":"Choi","year":"2019","journal-title":"EMBO Rep"},{"key":"2026030607501050000_75.4.733.61","doi-asserted-by":"crossref","DOI":"10.1038\/s41420-022-01259-z","article-title":"Targeting HER3 or MEK overcomes acquired Trastuzumab resistance in HER2-positive gastric cancer-derived xenograft","volume":"8","author":"Zhang","year":"2022","journal-title":"Cell Death Discov"},{"key":"2026030607501050000_75.4.733.62","doi-asserted-by":"crossref","first-page":"116014","DOI":"10.1016\/j.ejmech.2023.116014","article-title":"Identification of a novel potent CDK inhibitor degrading cyclinK with a superb activity to reverse trastuzumab-resistance in HER2-positive breast cancer in vivo","volume":"264","author":"Kuchukulla","year":"2024","journal-title":"Eur J Med Chem"},{"key":"2026030607501050000_75.4.733.63","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0598"},{"key":"2026030607501050000_75.4.733.64","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-12-0155-T"},{"key":"2026030607501050000_75.4.733.65","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-023-11447-4","article-title":"Wnt\/\u03b2-catenin pathway is a key signaling pathway to trastuzumab resistance in gastric cancer cells","volume":"23","author":"Kim","year":"2023","journal-title":"BMC Cancer"},{"key":"2026030607501050000_75.4.733.66","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-3292"},{"key":"2026030607501050000_75.4.733.67","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1434"},{"key":"2026030607501050000_75.4.733.68","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13237"},{"key":"2026030607501050000_75.4.733.69","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djy134"},{"key":"2026030607501050000_75.4.733.70","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28400"},{"key":"2026030607501050000_75.4.733.71","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.02.005"},{"key":"2026030607501050000_75.4.733.72","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)00620-7"},{"key":"2026030607501050000_75.4.733.73","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/j.immuni.2024.04.021","article-title":"Expression of the membrane tetraspanin claudin 18 on cancer cells promotes T lymphocyte infiltration and antitumor immunity in pancreatic cancer","volume":"57","author":"De Sanctis","year":"2024","journal-title":"Immunity"},{"key":"2026030607501050000_75.4.733.74","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-012683","article-title":"Dynamic modulation of claudin18.2 expression and remodeling of the tumor microenvironment in gastric cancer during chemo-immunotherapy","volume":"13","author":"Lim","year":"2025","journal-title":"J Immunother Cancer"},{"key":"2026030607501050000_75.4.733.75","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0140-6736(23)00725-0","article-title":"Trastuzumab deruxtecan versus treatment of physician\u2019s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial","volume":"401","author":"Andr\u00e9","year":"2023","journal-title":"Lancet"},{"key":"2026030607501050000_75.4.733.76","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02478-2"},{"key":"2026030607501050000_75.4.733.77","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2822"},{"key":"2026030607501050000_75.4.733.78","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-3985"}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gutjnl-2024-334667","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T15:50:47Z","timestamp":1772812247000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gutjnl-2024-334667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":78,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,3,6]]},"published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1136\/gutjnl-2024-334667"],"URL":"https:\/\/doi.org\/10.1136\/gutjnl-2024-334667","relation":{},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]}}}